Keep BRN on the ASX (for national pride reasons?) - Or help build the company and your wealth?
You need to sell this investment and move on. Life is too short.

Why a NASDAQ Move Could Benefit BrainChip (BRN)

1. Global Visibility & Legitimacy

NASDAQ is the world’s premier exchange for technology stocks. A listing there would immediately raise BrainChip’s profile with institutional investors, analysts, and the AI industry globally. BrainChip is attempting to lead in a global AI hardware revolution—not just an Australian story. The U.S. is where the industry lives and breathes.

2. Access to Deep Pools of Capital

The U.S. markets offer significantly more institutional capital. This matters when scaling cutting-edge semiconductors, which are expensive to design, test, and commercialize. If BrainChip wants to compete with companies like Synopsys, Mythic, Rain Neuromorphics, or even Intel’s neuromorphic efforts, it needs access to deeper pockets and a more sophisticated investor base.

3. Valuation Upside for Cutting-Edge IP

Many AI-focused U.S. chip firms trade at much higher revenue multiples than they would on the ASX. U.S. investors may better understand and price in the value of BrainChip’s neuromorphic IP portfolio, licensing revenue potential, defense/aerospace AI advantages, and future integration with edge AI and robotics.

4. Strategic Alignment with U.S. Customers & Partners

BrainChip is already forming U.S. partnerships—Frontgrade Gaisler (space), Raytheon (radar), Lockheed/Penn State (Quantum Ventura). A U.S. listing would align governance and proximity with the companies and defense agencies that may become its most valuable customers.

5. Increased Analyst Coverage & Liquidity

The NASDAQ attracts hundreds of institutional analysts who actively cover emerging tech. This could drive more consistent institutional buying, higher trading volumes, and better liquidity for shareholders—factors that can ultimately lead to higher long-term valuations.

6. Best-in-Class Comparables

As a NASDAQ-listed firm, BrainChip can be compared against other neuromorphic and AI hardware companies like BrainCorp, Mythic, SynSense, Esperanto AI, and SiMa.ai. This benchmarking could bring M&A attention, partnerships, and tech credibility.

7. Dual Listing Option Exists

Moving to the U.S. doesn’t have to mean abandoning the ASX. BrainChip could explore a dual-listing model where shares are traded both on NASDAQ and ASX, allowing retail Australians to stay involved.